» Articles » PMID: 16996554

Time Dependence of Protective Post-exposure Prophylaxis with Human Monoclonal Antibodies Against Pathogenic SHIV Challenge in Newborn Macaques

Abstract

In a primate model of postnatal virus transmission, we have previously shown that 1 h post-exposure prophylaxis (PEP) with a triple combination of neutralizing monoclonal antibodies (nmAbs) conferred sterilizing protection to neonatal macaques against oral challenge with pathogenic simian-human immunodeficiency virus (SHIV). Here, we show that nmAbs can also partially protect SHIV-exposed newborn macaques against infection or disease, when given as 12 or 24 h PEP, respectively. This work delineates the potential and the limits of passive immunoprophylaxis with nmAbs. Even though 24 h PEP with nmAbs did not provide sterilizing immunity to neonatal monkeys, it contained viremia and protected infants from acute disease. Taken together with our results from other PEP studies, these data show that the success of passive immunization depends on the nmAb potency/dose and the time window between virus exposure and start of immunotherapy.

Citing Articles

HIV-1 neutralizing antibodies provide sterilizing immunity by blocking infection of the first cells.

Stab V, Stahl-Hennig C, Ensser A, Richel E, Fraedrich K, Sauermann U Cell Rep Med. 2023; 4(10):101201.

PMID: 37804829 PMC: 10591032. DOI: 10.1016/j.xcrm.2023.101201.


Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children.

Dispinseri S, Cavarelli M, Tolazzi M, Plebani A, Jansson M, Scarlatti G Vaccines (Basel). 2021; 9(3).

PMID: 33799407 PMC: 7999787. DOI: 10.3390/vaccines9030260.


Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity.

Shapiro M, Cheever T, Malherbe D, Pandey S, Reed J, Yang E Nat Commun. 2020; 11(1):70.

PMID: 31911610 PMC: 6946664. DOI: 10.1038/s41467-019-13972-y.


Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

Hua C, Ackerman M Front Immunol. 2017; 8:1655.

PMID: 29234320 PMC: 5712301. DOI: 10.3389/fimmu.2017.01655.


Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Lewis G, DeVico A, Gallo R Proc Natl Acad Sci U S A. 2014; 111(44):15614-21.

PMID: 25349379 PMC: 4226080. DOI: 10.1073/pnas.1413550111.